Related references
Note: Only part of the references are listed.Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients
Adeel A. Butt et al.
CLINICAL INFECTIOUS DISEASES (2012)
Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management
Odile Picard et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2012)
Second-Phase Hepatitis C Virus RNA Decline During Telaprevir-Based Therapy Increases With Drug Effectiveness: Implications for Treatment Duration
Jeremie Guedj et al.
HEPATOLOGY (2011)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Drug Rash with Eosinophilia and Systemic Symptoms due to Telaprevir
H. Montaudie et al.
DERMATOLOGY (2010)
Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir
Fumitaka Suzuki et al.
JOURNAL OF CLINICAL VIROLOGY (2010)
Allergic Cross-Sensitivity Between Penicillin, Carbapenem, and Monobactam Antibiotics: What Are the Chances?
Jane Frumin et al.
ANNALS OF PHARMACOTHERAPY (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
Tara L. Kieffer et al.
HEPATOLOGY (2007)
Diagnosis, management, and treatment of hepatitis C
DB Strader et al.
HEPATOLOGY (2004)
Share Paper
